Scientific Evidence for the Updated Guidelines on Indications for Metabolic and Bariatric Surgery (IFSO/ASMBS)

Front

1 of 3 · Front

📘 GuidelineCh 11 · Bariatric & Metabolic Surgery

Scientific Evidence for the Updated Guidelines on Indications for Metabolic and Bariatric Surgery (IFSO/ASMBS)

In one breath

The 2024 evidence update behind the ASMBS/IFSO indications: a systematic report on 13 criteria — BMI thresholds, Asian populations, diabetes, age, adolescents, safety and long-term outcomes — finding the evidence for expanded eligibility strengthened, though several questions rest on observational data.

Edition2024 Evidence Update

Issued byInternational Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) and ASMBS

Place of issueInternational

PublishedObesity Surgery · 2024;34(11):3963–4096

⏳ Pending verification

FACE COLOURS Front — the summary · Back 1 — what it covers + key recommendations · Back 2 — evidence, changes + source

Back 1

2 of 3 · Back 1

Back colours mark the reading sections — the chapter colour is the band and chip.

§1 · What it covers

This guideline covers evidence behind 13 indications/criteria in the 2022 update, including BMI 30–34.9 kg/m², BMI ≥35 kg/m², Asian populations, diabetes, age, adolescents, and safety/long-term outcomes. It reports that evidence supporting expanded eligibility has strengthened, while also documenting heterogeneity and reliance on observational data for several questions.

Applies to: Population as stated in report; verify full source.

§2 · Key recommendations

evidence behind 13 indications/criteria in the 2022 update, including BMI 30–34.9 kg/m², BMI ≥35 kg/m², Asian populations, diabetes, age, adolescents, and safety/long-term outcomes.
It reports that evidence supporting expanded eligibility has strengthened, while also documenting heterogeneity and reliance on observational data for several questions.

FACE COLOURS Front — the summary · Back 1 — what it covers + key recommendations · Back 2 — evidence, changes + source

Back 2

3 of 3 · Back 2

Back colours mark the reading sections — the chapter colour is the band and chip.

§3 · Evidence & grading

the report uses systematic reviews, study-design and quality assessments, and compares evidence level and recommendation strength with the previous NIH criteria. Certainty is not uniformly high; many topics remain supported by retrospective cohorts, indirect comparisons, or expert consensus. It should therefore be read as support for shared decision-making rather than a claim that every threshold has high-certainty evidence.

§4 · What changed in this edition

Not yet established — pending verification.

§5 · Source & working link

De Luca M, et al. Scientific Evidence for the Updated Guidelines on Indications for Metabolic and Bariatric Surgery (IFSO/ASMBS). Obes Surg. 2024;34(11):3963–4096. doi:10.1007/s11695-024-07370-7 · PMID 39320627.

DOI — 10.1007/s11695-024-07370-7 ↗PubMed — PMID 39320627 ↗

Link check 2026-11-11: the record carries no original_url. The DOI and PubMed record (PMID 39320627) printed in the record's own text were fetched live — title, journal, volume and pages match; no Publisher row is printed.

Source: Tamer-supplied guideline index, intake 2026-11-10 (record #94, Domain 09) · Card built 2026-11-11 (Wave D) from the record itself; the §5.2 verification pass (UpToDate + Medscape → Perplexity → Tamer decision) has not yet run on this card. Completed in verification: title / issuedBy — The record's own key_recommendation text ('Exact title … Issuing societies …'), cross-verified at Crossref/PubMed for DOI 10.1007/s11695-024-07370-7, live 2026-11-11. ⚑ Conflict flag on the source record — documented cross-society disagreement (intake DOCX Table 2): Bariatric eligibility — ASMBS/IFSO 2022 vs NICE NG246 2025/2026 (this record is the 2024 evidence companion to the 2022 indications). Unresolved — pending the verification pass (UpToDate + Medscape → Perplexity → Tamer decision).

FACE COLOURS Front — the summary · Back 1 — what it covers + key recommendations · Back 2 — evidence, changes + source

gl-div11-asmbs-ifso-evidence-update-2024GS.code · Guidelines

More in Division 11 · Bariatric & Metabolic Surgery

📘 GuidelineCh 11 · Bariatric & Metabolic Surgery⏳ Pending verification

2022 ASMBS and IFSO Indications for Metabolic and Bariatric Surgery

The 2022 ASMBS/IFSO indications for metabolic and bariatric surgery: recommended at BMI above 35 kg/m² regardless of comorbidity, to be considered at BMI 30–34.9 kg/m² with metabolic disease, with lower thresholds for Asian populations.

2022 · American Society for Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO)

📘 GuidelineCh 11 · Bariatric & Metabolic Surgery⏳ Pending verification

2022 American Society of Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO): Indications for Metabolic and Bariatric Surgery

The 2022 ASMBS/IFSO indications statement (Domain 09 filing of the same guideline as the Domain 02 record): metabolic and bariatric surgery recommended at BMI above 35 kg/m², to be considered at BMI 30–34.9 kg/m² with metabolic disease, with adjusted Asian thresholds.

2022 · American Society for Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO)

📘 GuidelineCh 11 · Bariatric & Metabolic Surgery⏳ Pending verification

NICE NG246 (England and Wales-facing national guidance)

NICE guideline NG246 on overweight and obesity: specialist multidisciplinary assessment first, bariatric surgery considered inside the defined NHS pathway after appropriate assessment and prior weight-management approaches, with lower BMI thresholds for several ethnic groups.

NG246 — 2025 (updated 2026) · National Institute for Health and Care Excellence (NICE)